Haizheng Pharmaceutical announced on December 22 that the company received a notice from the US Food and Drug Administration that the HS387 tablet clinical trial application declared by the company has been approved by the US FDA, and clinical trials can be carried out in the US. HS387 tablets are intended for the treatment of advanced solid tumors such as high-grade serous ovarian cancer and non-small cell lung cancer.

Haizheng Pharmaceutical announced on December 22 that the company received a notice from the US Food and Drug Administration that the HS387 tablet clinical trial application declared by the company has been approved by the US FDA, and clinical trials can be carried out in the US. HS387 tablets are intended for the treatment of advanced solid tumors such as high-grade serous ovarian cancer and non-small cell lung cancer.